Published in:
01-02-2012 | Symposium: Papers Presented at the Annual Meetings of The Hip Society
Tantalum Augments for Paprosky IIIA Defects Remain Stable at Midterm Followup
Authors:
Daniel J. Del Gaizo, MD, Vamsi Kancherla, MD, Scott M. Sporer, MD, Wayne G. Paprosky, MD
Published in:
Clinical Orthopaedics and Related Research®
|
Issue 2/2012
Login to get access
Abstract
Background
Initial reports with short-term followup of porous tantalum acetabular components and augments for Paprosky IIIA acetabular defects demonstrate high hip scores, low rates of aseptic loosening, and low rates of complications. However, longer-term followup with a larger cohort is needed to determine the durability of these reconstructions.
Questions/purposes
We therefore determined the functional scores, rates of aseptic loosening, and complications in patients with Paprosky IIIA acetabular defects treated with porous tantalum acetabular components and augments.
Methods
We retrospectively reviewed 37 acetabular revisions in 36 patients (one patient with bilateral revisions) treated with a porous tantalum acetabular component and augment. All patients had defects classified as Type IIIa using the system of Paprosky et al. Harris hip scores were obtained and radiographic examination was performed before surgery and through most recent followup. The minimum followup was 26 months (mean, 60 months; range, 26–106 months).
Results
One patient developed aseptic loosening of the acetabular reconstruction requiring revision; seven other patients required further surgery for periprosthetic femoral fracture (two), acute infection (three), and recurrent dislocation (two). Thirty-five of 37 hips had no or occasional pain at final followup. Mean Harris hip scores improved from 33.0 preoperatively (range, 12.6–58.7) to 81.5 postoperatively (range, 27.0–99.8).
Conclusions
Although the complication rate requiring further surgery was considerable, most patients with these reconstructions had pain relief and reasonable function with low rates of loosening at midterm followup.
Level of Evidence
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.